DK2694510T3 - Imidazopyridaziner som akt-kinasehæmmere - Google Patents

Imidazopyridaziner som akt-kinasehæmmere Download PDF

Info

Publication number
DK2694510T3
DK2694510T3 DK12713963.2T DK12713963T DK2694510T3 DK 2694510 T3 DK2694510 T3 DK 2694510T3 DK 12713963 T DK12713963 T DK 12713963T DK 2694510 T3 DK2694510 T3 DK 2694510T3
Authority
DK
Denmark
Prior art keywords
alkyl
aryl
hydrogen
phenyl
nhc
Prior art date
Application number
DK12713963.2T
Other languages
English (en)
Inventor
Lars Bärfacker
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bömer
William Johnston Scott
Andrea Hägebarth
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of DK2694510T3 publication Critical patent/DK2694510T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (14)

1. Forbindelse med formlen (I)
hvor RI er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C (0) 0R8, C (0) (l-6C-alkyl) , NHC (0) (l-6C-alkyl) , NHS(0)2R11, NHC(0)NHRI1, -S (0)n-l-6C-alkyl, -S(0)2NR5R5 eller en gruppe valgt blandt l-6C-alkyl, l-6C-alkoxy, 3-7C-cycloalkyl, aryl, heteroaryl, -(l-6C-alkyl)-aryl, -(l-6C-alkyl)-heteroaryl, -0-(3-7C-cycloalkyl), -0-aryl, -0-(3-7C-heterocyclyl), -0- heteroaryl, -0-(1-6C-alkyl)-heteroaryl, -0-(l-6C-alkyl)- (3-7C- heterocyclyl), -0-(l-6C-alkyl)-aryl, 2-6C-alkenyl, 2-6C- alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-6C-alkyl, l-4C-halogenalkyl, l-6C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC (0) NHRI 1, -NHS(0)2R11, 3-7C-cycloalkyl, 3-7C-heterocyclyl, aryl, R2 er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C(0)0R8, C(0) (l-6C-alkyl), NHC (0) (l-6C-alkyl), NHS(0)2R11, NHC(0)NHR11, -S(0)n-l-6C-alkyl, -S(0)2NR5R6 eller en gruppe valgt blandt l-6C-alkyl, l-6C-alkoxy, 3-7C-cycloalkyl, aryl, heteroaryl, -(l-6C-alkyl)-aryl, -(l-6C-alkyl)-heteroaryl, -0-(3-7C-cycloalkyl), -0-aryl, -0-(3-7C-heterocyclyl), -0- heteroaryl, -0-(1-6C-alkyl)-heteroaryl, -0-(l-6C-alkyl)-(3 — 7 C — heterocyclyl), -0-(1-6C-alkyl)-aryl, 2-6C-alkenyl, 2-6C- alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-6C-alkyl, l-4C-halogenalkyl, l-6C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC (0) NHR11, -NHS(0)2R11, 3-7C-heterocyclyl, aryl, R3 er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C(0)0R8, C(0) (l-6C-alkyl), NHS(0)2R11, NHC(0)NHR11, -S(0)n-1- 6C-alkyl, -S(0)2NR5R6 eller en gruppe valgt blandt l-6C-alkyl, l-6C-alkoxy, 3-7C-cycloalkyl, aryl, heteroaryl, -(l-6C-alkyl)-aryl, -(l-6C-alkyl)-heteroaryl, -0-(3-7C-cycloalkyl), -0-aryl, -0-(3-7C-heterocyclyl), -O-heteroaryl, -0-(l-6C-alkyl)- heteroaryl, -0-(l-6C-alkyl)-(3-7C-heterocyclyl), -0-(l-6C- alkyl)-aryl, NHC(O)(1-6C-alkyl), 2-6C-alkenyl, 2-6C-alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-6C-alkyl, l-4C-halogenalkyl, l-6C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC(O)NHRll, -NHS(0)2R11, 3-7C-heterocyclyl, aryl, R4 er phenyl, som eventuelt er substitueret en, to eller tre gange, identisk eller forskelligt, med et halogenatom; R5 er hydrogen, l-6C-alkyl, R6 er hydrogen, l-6C-alkyl, R8 er hydrogen, l-6C-alkyl, som eventuelt er substitueret med hydroxy, R9 er hydrogen, l-6C-alkyl, RIO er hydrogen, l-6C-alkyl, Ril er hydrogen, l-6C-alkyl, X, Y er CH2; n er 0, 1, 2; eller et N-oxid, et salt, en tautomer eller en stereoisomer af forbindelsen eller et salt af N-oxidet, tautomeren eller stereoisomeren.
2. Forbindelse ifølge krav 1 hvor RI er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C(0)0R8, C(0)(l-3C-alkyl), NHC(0)(l-6C-alkyl), NHS(0)2R11, NHC(O)NHRll, -S(0)n-l-3C-alkyl, -S(0)2NR5R6 eller en gruppe valgt blandt l-3C-alkyl, l-3C-alkoxy, 3-6C-cycloalkyl, aryl, heteroaryl, -(l-3C-alkyl)-aryl, - (l-3C-alkyl)-heteroaryl, -0-(3-6C-cycloalkyl), -0-aryl, -0-(3-6C-heterocyclyl), -0- heteroaryl, -0-(l-3C-alkyl)-heteroaryl, -0-(l-3C-alkyl)-(3-6C-heterocyclyl), -0-(l-3C-alkyl)-aryl, 2-3C-alkenyl, 2-3C- alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-3C-alkyl, l-3C-halogenalkyl, l-3C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC (O)NHRll, -NHS(0)2RH, 3-6C-cycloalkyl, 3-6C-heterocyclyl, aryl, R2 er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C(0)0R8, C(0)(l-3C-alkyl), NHC(0)(l-3C-alkyl), NHS(0)2R11, NHC(0)NHR11, -S(0)n-l-3C-alkyl, -S(0)2NR5R6 eller en gruppe valgt blandt l-3C-alkyl, l-3C-alkoxy, 3-6C-cycloalkyl, aryl, heteroaryl, -(l-3C-alkyl)-aryl, -(l-3C-alkyl)-heteroaryl, -0-(3-6C-cycloalkyl), -0-aryl, -0-(3-6C-heterocyclyl), -0- heteroaryl, -0-(l-3C-alkyl)-heteroaryl, -0-(l-3C-alkyl)- (3-6C-heterocyclyl), -0-(l-3C-alkyl)-aryl, 2-3C-alkenyl, 2-3C- alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-3C-alkyl, l-3C-halogenalkyl, l-3C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC (O)NHRll, -NHS(0)2RH, 3-6C-heterocyclyl, aryl, R3 er hydrogen, hydroxy, NR5R6, halogen, cyano, CO(NR8R9), C(0)0R8, C (0) (l-3C-alkyl), NHS(0)2R11, NHC(0)NHR11, -S(0)n-1“ 3C-alkyl, -S(0)2NR5R6 eller en gruppe valgt blandt l-3C-alkyl, l-3C-alkoxy, 3-6C-cycloalkyl, aryl, heteroaryl, -(l-3C-alkyl)-aryl, -(l-3C-alkyl)-heteroaryl, -0-(3-6C-cycloalkyl), -0-aryl, -0-(3-6C-heterocyclyl), -O-heteroaryl, -0-(l-3C-alkyl)- heteroaryl, -0-(l-3C-alkyl)-(3-6C-heterocyclyl), -0-(1-3C- alkyl)-aryl, NHC(0)(l-3C-alkyl), 2-3C-alkenyl, 2-3C-alkynyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: hydroxy, halogen, l-3C-alkyl, l-3C-halogenalkyl, l-3C-alkoxy, -NR8R9, cyano, -C(0)NR8R9, -C(O)OR10, -NHC(0)R11, -NHC (O)NHRll, -NHS(0)2RH, 3-6C-heterocyclyl, aryl, R4 er phenyl, som eventuelt er substitueret en, to eller tre gange, identisk eller forskelligt, med et halogenatom; R5 er hydrogen, l-3C-alkyl, R6 er hydrogen, l-3C-alkyl, R8 er hydrogen, l-3C-alkyl, som eventuelt er substitueret med hydroxy, R9 er hydrogen, l-3C-alkyl, RIO er hydrogen, l-3C-alkyl, Ril er hydrogen, l-3C-alkyl, X, Y er CH2; n er 0, 1, 2; eller et N-oxid, et salt, en tautomer eller en stereoisomer af forbindelsen eller et salt af N-oxidet, tautomeren eller stereoisomeren.
3. Forbindelse ifølge krav 1 hvor RI er hydrogen, hydroxy, NR5R6, CO(NR8R9), C(0)0R8, NHC(0)(1- 6C-alkyl) eller en gruppe valgt blandt l-6C-alkyl, 3-70 cycloalkyl, aryl, heteroaryl, l-4C-alkoxy, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: halogen, 1-60 alkyl, l-6C-alkoxy, -C(O)ORl0, 3-7-cycloalkyl, aryl, R2 er hydrogen, l-6C-alkyl, R3 er hydrogen, hydroxy, NR5R6, halogen, CO(NR8R9), C(0)0R8, C(O)(l-6C-alkyl), NHS(0)2R11, S(O)n-l-6C-alkyl eller en gruppe valgt blandt l-6C-alkyl, l-6C-alkoxy-aryl, NHC(O)(l-6C-alkyl), 2-6C-alkenyl, hvor gruppen eventuelt er substitueret en eller flere gange, identisk eller forskelligt, med en substituent valgt blandt: halogen, -C(O)OR10, R4 er phenyl, R5 er hydrogen, R6 er hydrogen, R8 er hydrogen, l-4C-alkyl, som eventuelt er substitueret med hydroxy, R9 er hydrogen, l-4C-alkyl, R10 er l-4C-alkyl, Ril er l-4C-alkyl, X, Y er CH2, n er 0, 1, 2; eller et N-oxid, et salt, en tautomer eller en stereoisomer af forbindelsen eller et salt af N-oxidet, tautomeren eller stereoisomeren.
4. Forbindelse ifølge krav 1, hvor RI er hydrogen, hydroxy, amino, methoxy, ethoxy, butoxy, pyridin-3-yl, pyridin-4-yl, pyrazol-3-yl, l-methyl-pyrazol-3-yl, imidazol-2-yl, methyl, propyl, -0-(CH2)-0-CH3, -0-CH2- phenyl, -0-CH2-cyclopropyl, -C(0)0CH3, -C(0)-NHCH3, -C(0)-NH2, 4-fluorphenyl, - (CH2) 2-C (0) 0CH3, cyclopropyl, -NH-C(0)CH3, R2 er hydrogen, methyl, R3 er hydrogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, -0-CH2-C (0) 0CH3, -S-CH3, -S02-CH3, brom, chlor, trifluormethyl, C(0)NH2, COOH, C(0)0CH3, C(0)0CH2CH3, C(0)NH2, C(0)NHCH3, C(0)N(CH3)2, C (0)NH (CH2) 2-OH, -CH=CH2, 4-f luorphenyl, NHC(0)CH3, NHC(0)CF3, NH-S02-CH3, C(0)CH3, R4 er phenyl, X, Y er CH2, eller et N-oxid, et salt, en tautomer eller en stereoisomer af forbindelsen eller et salt af N-oxidet, tautomeren eller stereoisomeren.
5. Forbindelse ifølge krav 1, som er valgt fra gruppen bestående af
6. Forbindelse ifølge krav 5, som er valgt fra gruppen bestående af
7. Forbindelse ifølge krav 5, som er valgt fra gruppen bestående af
8. Fremgangsmåde til fremstilling af forbindelser med den almene formel (I) ifølge krav 1 ved omsætning af en forbindelse med den almene formel (II)
hvor R1-R4 har den betydning, som er angivet i krav 1, og Rx,Ry er R6 eller en beskyttelsesgruppe, hvor omdannelse til en forbindelse med den almene formel (I) opnås ved anvendelse af en passende afbeskyttelsesreaktion.
9. Forbindelse ifølge krav 1 til anvendelse til behandling af sygdomme.
10. Forbindelse til anvendelse ifølge krav 9, hvorved sygdommen er benign neoplasi eller malign neoplasi.
11. Forbindelse ifølge krav 1-7 til anvendelse til behandling af mammacancer.
12. Farmaceutisk sammensætning, som omfatter mindst én forbindelse med den almene formel (I) ifølge et hvilket som helst af kravene 1-7 sammen med mindst ét farmaceutisk acceptabelt additiv.
13. Farmaceutisk sammensætning, som omfatter en første aktiv bestanddel, der er mindst én forbindelse med den almene formel (I) ifølge et hvilket som helst af kravene 1-7, og en anden aktiv bestanddel, som er mindst ét yderligere anticancermiddel.
14. Sammensætning ifølge krav 12 eller 13 til anvendelse til behandling af mammacancer.
DK12713963.2T 2011-04-07 2012-04-05 Imidazopyridaziner som akt-kinasehæmmere DK2694510T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2694510T3 true DK2694510T3 (da) 2016-01-18

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12713963.2T DK2694510T3 (da) 2011-04-07 2012-04-05 Imidazopyridaziner som akt-kinasehæmmere

Country Status (42)

Country Link
US (2) US9206185B2 (da)
EP (1) EP2694510B1 (da)
JP (1) JP5906303B2 (da)
KR (1) KR20140022057A (da)
CN (1) CN103596957B (da)
AP (1) AP3597A (da)
AR (1) AR087148A1 (da)
AU (1) AU2012238589B2 (da)
BR (1) BR112013025777A2 (da)
CA (1) CA2832374A1 (da)
CL (1) CL2013002878A1 (da)
CO (1) CO6862145A2 (da)
CR (1) CR20130515A (da)
CU (1) CU24263B1 (da)
CY (1) CY1117163T1 (da)
DK (1) DK2694510T3 (da)
DO (1) DOP2013000226A (da)
EA (1) EA024890B1 (da)
EC (1) ECSP13013008A (da)
ES (1) ES2558780T3 (da)
GT (1) GT201300238A (da)
HR (1) HRP20160011T1 (da)
HU (1) HUE026323T2 (da)
IL (1) IL228567A0 (da)
JO (1) JO3068B1 (da)
MA (1) MA35016B1 (da)
ME (1) ME02316B (da)
MX (1) MX336865B (da)
NI (1) NI201300105A (da)
PE (1) PE20141380A1 (da)
PL (1) PL2694510T3 (da)
PT (1) PT2694510E (da)
RS (1) RS54480B1 (da)
SG (1) SG193631A1 (da)
SI (1) SI2694510T1 (da)
SM (1) SMT201600001B (da)
TN (1) TN2013000400A1 (da)
TW (1) TWI535719B (da)
UA (1) UA111739C2 (da)
UY (1) UY34006A (da)
WO (1) WO2012136776A1 (da)
ZA (1) ZA201307223B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (da) 2008-06-16 2017-06-26 Univ Tennessee Res Found Forbindelse til behandling af cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
JO3068B1 (ar) * 2011-04-07 2017-03-15 Bayer Ip Gmbh إيميدازوبيريميدينات كمثبطات كيناز akt
US9260435B2 (en) * 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
CN104066736B (zh) * 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
WO2014085371A1 (en) * 2012-11-30 2014-06-05 Glaxosmithkline Llc Novel pharmaceutical composition
CN109568312A (zh) * 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
JP2016517434A (ja) * 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
CA2936024A1 (en) * 2014-01-09 2015-07-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246621A4 (en) 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
US6908929B2 (en) 2000-03-31 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004096131A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EA009038B1 (ru) 2003-07-30 2007-10-26 Лабораториос С.А.Л.В.А.Т., С.А. Замещенные имидазопиримидины для предупреждения и лечения рака
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
WO2006036395A2 (en) 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
US20070255064A1 (en) 2004-08-24 2007-11-01 Basf Aktiengesellschaft Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids
CA2589084A1 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
BRPI0610863A2 (pt) 2005-05-20 2010-08-03 Array Biopharma Inc compostos inibidores de raf e métodos para sua utilização
NZ563423A (en) 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
EP2167491A1 (en) * 2007-06-08 2010-03-31 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
PA8793301A1 (es) 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
PA8793201A1 (es) 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Pirimidinas bicíclicas fusinadas
JP2011507902A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー 肝臓Ｘ受容体のモジュレーターとしてのイミダゾ［１，２−ｂ］ピリダジン化合物
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5777526B2 (ja) * 2009-02-13 2015-09-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジン類
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
CN103384670B (zh) * 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
JO3068B1 (ar) * 2011-04-07 2017-03-15 Bayer Ip Gmbh إيميدازوبيريميدينات كمثبطات كيناز akt

Also Published As

Publication number Publication date
TWI535719B (zh) 2016-06-01
EA024890B1 (ru) 2016-10-31
IL228567A0 (en) 2013-12-31
NI201300105A (es) 2014-07-14
AU2012238589B2 (en) 2017-02-16
CL2013002878A1 (es) 2014-05-02
TW201245204A (en) 2012-11-16
EP2694510A1 (en) 2014-02-12
AR087148A1 (es) 2014-02-26
KR20140022057A (ko) 2014-02-21
US9604989B2 (en) 2017-03-28
UA111739C2 (uk) 2016-06-10
JP2014510127A (ja) 2014-04-24
AP2013007215A0 (en) 2013-10-31
SMT201600001B (it) 2016-02-25
US20140113901A1 (en) 2014-04-24
MA35016B1 (fr) 2014-04-03
CN103596957B (zh) 2016-12-07
CU24263B1 (es) 2017-07-04
HRP20160011T1 (hr) 2016-02-12
CA2832374A1 (en) 2012-10-11
ECSP13013008A (es) 2013-12-31
US20150368250A1 (en) 2015-12-24
PL2694510T3 (pl) 2016-03-31
CO6862145A2 (es) 2014-02-10
EA201301130A1 (ru) 2014-07-30
DOP2013000226A (es) 2013-11-15
PT2694510E (pt) 2016-02-08
ES2558780T3 (es) 2016-02-08
HUE026323T2 (en) 2016-05-30
MX336865B (es) 2016-02-04
CU20130135A7 (es) 2014-02-28
AP3597A (en) 2016-02-19
UY34006A (es) 2012-10-31
ZA201307223B (en) 2014-12-23
BR112013025777A2 (pt) 2016-12-20
WO2012136776A1 (en) 2012-10-11
PE20141380A1 (es) 2014-10-18
JP5906303B2 (ja) 2016-04-20
RS54480B1 (en) 2016-06-30
TN2013000400A1 (en) 2015-03-30
NZ616270A (en) 2015-09-25
EP2694510B1 (en) 2015-10-14
SI2694510T1 (sl) 2016-02-29
ME02316B (me) 2016-06-20
AU2012238589A1 (en) 2013-11-07
SG193631A1 (en) 2013-11-29
CN103596957A (zh) 2014-02-19
JO3068B1 (ar) 2017-03-15
CY1117163T1 (el) 2017-04-05
MX2013011699A (es) 2014-01-31
GT201300238A (es) 2015-04-06
US9206185B2 (en) 2015-12-08
CR20130515A (es) 2013-12-04

Similar Documents

Publication Publication Date Title
DK2694510T3 (da) Imidazopyridaziner som akt-kinasehæmmere
US9951086B2 (en) Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
US9260435B2 (en) Substituted imidazopyrazines as Akt kinase inhibitors
TW201412740A (zh) 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP3233866B1 (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
US9370517B2 (en) Substituted pyrazolopyrimidines as Akt kinase inhibitors
EP2651949B1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
NZ616270B2 (en) Imidazopyridazines as akt kinase inhibitors
TW201348240A (zh) 噻吩并嘧啶